Allopurinol–thiopurine combination therapy in inflammatory bowel disease: are there genetic clues to this puzzle?
15-gene signature predicts which patients benefit from postsurgery chemotherapy
NIH expands key pharmacogenomics resource
EGF receptor signaling network offers insights into improving the efficacy of targeted cancer therapy
The watchdog of better survival rates in stomach cancer: miRNA-451
Tumor sensitivity and resistance to artesunate
c-Myc/Max-regulated genes in artesunate cancer cytotoxicity
Signaling pathways in dihydroartemisinin suppression of tumor invasion
Dihydroartemisinin inhibition of gemcitabine-induced NF-κB activity
Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with Type 2 diabetes mellitus
Genetic polymorphisms in sex hormone metabolizing genes and drug response in women with epilepsy
CYP1A2 genetic polymorphisms are associated with treatment response to the antidepressant paroxetine
Quantitative analysis and modeling of glucocorticoid-controlled gene expression
Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis
Systematic review of pharmacoeconomic studies of pharmacogenomic tests
Identifying genomic and developmental causes of adverse drug reactions in children
Opening the gate for genomics data into clinical research: a use case in managing patients’ DNA samples from the bench to drug development
Pharmacogenetics of controlled ovarian hyperstimulation: time to corroborate the clinical utility of FSH receptor genetic markers
Evaluating a newly developed pharmacogenetic array: screening in a Spanish population
Acknowledgements